Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 7/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085457 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL2084587 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL959414 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL2087915 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL3623709 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL3628294 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL2087982 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL2085108 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL10891331 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 | |
| SCHEMBL3623431 | 1.00 | HMGCR (0.52) | HMGCRPTPN7SELPRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740724-B1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO PHARMACEUTICAL CO (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9085523-B2 | Compound for treating cartilage disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20140171388-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2740724-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-7858650-B2 | Medicinal composition for inhalation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7402696-B2 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20080114043-A1 | Medicinal Composition for Inhalation | ONO PHARMACEUTICAL CO., LTD (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1806148-A1 | MEDICINAL COMPOSITION FOR INHALATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070105899-A1 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-6812252-B2 | ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-1156054-B1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030181764-A1 | Acylsulfonamide derivatives | AJINOMOTO CO. INC (JP) | 2003-09-25 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1316548-A1 | ACYLSULFONAMIDE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6495533-B1 | TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1156054-A1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114043-A1 | Medicinal Composition for Inhalation | PTGER2, PTGER1, PTGIS | HMGCR 2050/4885PTPN7 2925/4885SELP 1502/4885 |
| US-20030181764-A1 | Acylsulfonamide derivatives | DPP4, SLC5A2, GLP1R | HMGCR 553/4885PTPN7 704/4885SELP 3476/4885 |
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | HMGCR 136/4885PTPN7 2202/4885SELP 4533/4885 |
| US-20140171388-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | COL2A1, COL1A1, ADAMTS1 | HMGCR 110/4885PTPN7 3505/4885SELP 1004/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | HMGCR 146/4885PTPN7 1405/4885SELP 4015/4885 |
| US-20070105899-A1 | Benzene compounds | ACACB, ACACA, FABP4 | HMGCR 276/4885PTPN7 2913/4885SELP 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.